All the news

Showing 10 of 18 articles from: NAFLD

Get an RSS feed of these articles

Show

Pharma turn to NASH unlikely to mirror meteoric rise of hep C

Bio Pharma Dive / 22 May 2018
Costs Balloon after Cirrhosis Diagnosis for NAFLD/NASH

MedPage Today Gastroenterology / 17 April 2018
'Wake-up call' over liver disease risks due to weight

BBC News / 17 April 2018
Cenicriviroc treatment improves liver fibrosis in people with NASH

Liz Highleyman / 13 April 2018

Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, continued to show an anti-fibrotic effect in people with non-alcoholic steatohepatitis (NASH) after two years of follow-up, according to a ...
Mediterranean diet reduces liver fat, risk for NAFLD

Healio Hepatology / 03 April 2018
NAFLD May Be Easier to Prevent than Treat

MedPage Today / 03 April 2018
Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

Eurekalert Medicine & Health / 22 November 2017
Fatty Liver Common After Direct-Acting Antivirals for Hep C

Medscape (requires free registration) / 01 November 2017
New EACS treatment guidelines

Keith Alcorn / 31 October 2017

Everyone with HIV and hepatitis C virus (HCV) co-infection should receive direct-acting antiviral treatment for hepatitis C and should receive the same treatment for hepatitis C as people with hepatitis C monoinfection, ...
Experimental therapy improves liver fat and fibrosis in people with NASH

Liz Highleyman / 30 October 2017

GS-0976, an acetyl-CoA carboxylase (ACC) inhibitor being developed by Gilead Sciences, led to significant reductions in liver fat accumulation and fibrosis in people with non-alcoholic steatohepatitis (NASH), according to phase 2 study results ...